Squarepoint
AVBP icon

Squarepoint’s ArriVent BioPharma AVBP Stock Holding History

Squarepoint’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Sell
55,432
-131,060
-70% -$2.96M ﹤0.01% 2566
2025
Q4 		$3.75M Buy
186,492
+58,185
+45% +$1.21M ﹤0.01% 1641
2025
Q3 		$2.37M Sell
128,307
-76,048
-37% -$1.49M ﹤0.01% 1961
2025
Q2 		$4.45M Buy
204,355
+185,929
+1,009% +$3.86M ﹤0.01% 1539
2025
Q1 		$341K Buy
+18,426
New +$451K ﹤0.01% 3640

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's AVBP Position: Q1 2026 in Review

Squarepoint reduced its ArriVent BioPharma (AVBP) stake by 70% in Q1 2026, selling an estimated $2.96M and leaving 55,432 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2566.

Squarepoint first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.45M in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Squarepoint held 55,432 shares of ArriVent BioPharma worth $1.28M as of Q1 2026.
  • Squarepoint sold 131,060 ArriVent BioPharma shares in Q1 2026, an estimated $2.96M.
  • ArriVent BioPharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2566 holding.
  • Squarepoint first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • Squarepoint's ArriVent BioPharma position peaked at $4.45M in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.